Urology News and Research

Latest Urology News and Research

Imprimis has exclusive US commercial rights for patented Hep-Lido-A formulation

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced it now has the exclusive US commercial rights to the patented compounded alkalinized lidocaine and heparin formulation ("Hep-Lido-A" or "HLA") for the treatment of interstitial cystitis ("IC"), commonly referred to as painful bladder syndrome ("PBS").

28 Apr 2015

Dan Theodorescu awarded Barringer Medal for distinguished contributions to urology

Dan Theodorescu, MD, PhD, director of the NCI-designated University of Colorado Cancer Center and professor of Urology and Pharmacology at the University of Colorado School of Medicine was awarded the Barringer Medal this past Saturday from the American Association of Genitourinary Surgeons for his distinguished contributions to urology.

25 Apr 2015

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).

25 Apr 2015

New educational resource to help improve knowledge, treatment of Inflammatory Bowel Disease

A new educational resource for doctors and healthcare professionals will help improve knowledge and treatment of Inflammatory Bowel Disease (IBD). The Inflammatory Bowel Disease Resource Centre was developed by Elsevier, the journal Digestive and Liver Disease, and was made possible through an educational grant from Ferring Pharmaceuticals.

22 Apr 2015

New collaboration brings comprehensive genomic profiling to UC Davis

The UC Davis Comprehensive Cancer Center and the Department of Pathology and Laboratory Medicine have entered into a collaboration with Foundation Medicine, a leading molecular information company. The collaboration brings comprehensive genomic profiling into standard of care at UC Davis, allowing physicians to prescribe the most effective, targeted cancer treatments to patients based on the genomic information specific to each individual's cancer.

21 Apr 2015

Donald S. Coffey to receive Margaret Foti Award at AACR Annual Meeting 2015

Donald S. Coffey, PhD, will be honored with the ninth annual American Association for Cancer Research Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

17 Apr 2015

LABORIE completes acquisition of Medical Measurement Systems

LABORIE Medical Technologies has completed its acquisition of Medical Measurement Systems. MMS is headquartered in Enschede, The Netherlands, with a German subsidiary in Bottrop and US operations in Dover, New Hampshire.

13 Apr 2015

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...

13 Apr 2015

Researchers link loss of WAVE1 gene to lethal form of prostate cancer

Researchers at Upstate Medical University and Harvard University have linked the loss of key gene, WAVE1, to a lethal form of prostate cancer, according to a study published in the journal Oncotarget.

9 Apr 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

Two case studies provide potential new avenue for treatment of kidney cancer

UT Southwestern Medical Center Kidney Cancer Program investigators have published what is believed to be the first reported successful use of stereotactic body radiation therapy for an often deadly complication of kidney cancer.

8 Apr 2015

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

6 Apr 2015

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.

6 Apr 2015

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer.

2 Apr 2015

Loyola takes holistic approach to help couples manage their sexual health

Sexual dysfunction is common among couples, yet it often goes untreated, according to specialists at Loyola University Health System's Sexual Wellness Clinic.

1 Apr 2015

Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Bladder cancer is the seventh leading cancer affecting men worldwide and in the United States, it is the fourth leading cancer. Each year, about 350,000 cases are being detected worldwide, and the disease claims 165,000 lives every year.

31 Mar 2015

USC Hospitalist Leadership Fellowship Program launched at ApolloMed

Apollo Medical Holdings, Inc., an integrated physician-centric healthcare delivery company, and the Keck School of Medicine of the University of Southern California (USC) Internal Medicine Residency Program today announced the launch of the USC Hospitalist Leadership Fellowship Program at ApolloMed.

30 Mar 2015

Researchers evaluate decision aids for patient's choice of localised prostate cancer treatment

Doctors strive to make treatment decisions together with their patients - but is the decision really shared? According to adjunct professor Kari Tikkinen, shared decision-making isn't easy, and clinicians need help. The international research group led by Tikkinen has studied the decision aids for treatment choice of localised prostate cancer

30 Mar 2015

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.

26 Mar 2015

Mayo Clinic Center for Tuberculosis introduces new medical journal

The Mayo Clinic Center for Tuberculosis, a regional training and consultation center at Mayo Clinic's campus in Rochester, Minn, is today launching a new medical journal, the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.

25 Mar 2015

Urology News and Research

Latest Urology News and Research

Imprimis has exclusive US commercial rights for patented Hep-Lido-A formulation

Dan Theodorescu awarded Barringer Medal for distinguished contributions to urology

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

New educational resource to help improve knowledge, treatment of Inflammatory Bowel Disease

New collaboration brings comprehensive genomic profiling to UC Davis

Donald S. Coffey to receive Margaret Foti Award at AACR Annual Meeting 2015

LABORIE completes acquisition of Medical Measurement Systems

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Researchers link loss of WAVE1 gene to lethal form of prostate cancer

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Two case studies provide potential new avenue for treatment of kidney cancer

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Loyola takes holistic approach to help couples manage their sexual health

Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

USC Hospitalist Leadership Fellowship Program launched at ApolloMed

Researchers evaluate decision aids for patient's choice of localised prostate cancer treatment

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Mayo Clinic Center for Tuberculosis introduces new medical journal

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Urology News and Research

Latest Urology News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in